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ORIGINAL ARTICLE
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Abstract
An estimated 1% or less of nanoparticles (NPs) deposited in the lungs translocate to systemic
circulation and enter other organs; however, this estimation may not be accurate given the low
sensitivity of existing in vivo NP detection methods. Moreover, the biological effects of such low
levels of translocation are unclear. We employed a nano-scale hyperspectral microscope to
spatially observe and spectrally profile NPs in tissues and blood following pulmonary
deposition in mice. In addition, we characterized effects occurring in blood, liver and heart at
the mRNA and protein level following translocation from the lungs. Adult female C57BL/6 mice
were exposed via intratracheal instillation to 18 or 162mg of industrially relevant titanium
dioxide nanoparticles (nano-TiO2) alongside vehicle controls. Using the nano-scale hyperspec-
tral microscope, translocation to heart and liver was confirmed at both doses, and to blood at
the highest dose, in mice analyzed 24 h post-exposure. Global gene expression profiling and
ELISA analysis revealed activation of complement cascade and inflammatory processes in heart
and specific activation of complement factor 3 in blood, suggesting activation of an early innate
immune response essential for particle opsonisation and clearance. The liver showed a subtle
response with changes in the expression of genes associated with acute phase response. This
study characterizes the subtle systemic effects that occur in liver and heart tissues following
pulmonary exposure and low levels of translocation of nano-TiO2 from lungs.
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Introduction
The increased production and use of NPs (defined as particles
5100 nm in at least one dimension) in various consumer products
(paints, sunscreens and cosmetics), nano-medicines and diagnos-
tics has increased the risk of human exposure to these particles
(IARC, 2010). Target organ toxicity, especially pulmonary
toxicity following exposure via inhalation, has been the focus of
several studies in the last decade (Ferin et al., 1992; Grassian
et al., 2007; Renwick et al., 2004; Warheit et al., 2007); however,
very few in vivo studies have investigated the effects of
translocation of particles to non-target tissues. In biodistribution
studies using isotope-tagged or fluorescence labelled particles,
a small fraction (less than 1%) of NPs [gold nanoparticles
(2–40 nm), titanium dioxide nanoparticles (22 nm), ultrafine
iridium particles (15 and 80 nm) radiolabeled with 192iridium
(192Ir), carbon nanoparticles (25 nm) spiked with radio-labeled
primary iridium (192Ir) and isotopic ultrafine carbon particles
(13C; 20–29 nm)] deposited in lungs were shown to translocate to
systemic circulation and reach extra-pulmonary organs including
heart and liver (Geiser & Kreyling, 2010; Geiser et al., 2005;
Kreyling et al., 2002; Muhlfeld et al., 2007; Nemmar et al.,
2002a,b; Oberdorster et al., 2002; Sadauskas et al., 2007, 2009b).
These studies did not elucidate the systemic effects of such
particle translocation and the potential influence of doping the
particles with isotope or fluorescent tags on translocation was not
clear. Moreover, the existing analytical methods, for example
inductively coupled plasma mass spectrometry (ICP-MS), are not
always sensitive enough to detect the low amounts NPs that
translocate. In addition, optical microscopic methods require
isotope or florescence tagging of particles, which results in
increasing the particle size and may influence their translocation.
We previously investigated the effects of nano-titanium
dioxide particles (nano-TiO2) exposure and deposition in mouse
lung tissue, and showed strong pulmonary inflammation, acute
phase response and systemic circulation of cytokines and acute
phase proteins (Husain et al., 2013). The first objective of this
study was to employ hyperspectral microscopy to detect trans-
location of non-doped NPs to heart and liver tissues following
direct deposition in lungs in these mice [i.e. heart and liver tissue
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collected from Husain et al. (2013)]. This technique enables
optical imaging and qualitative spectral analysis of NPs in tissues
or cells without requiring post-processing of samples or special
tagging of NPs with fluorescence.
Given that the translocation to extra-pulmonary organs is
expected to be very low, the potential biological effects of such
translocation are generally assumed to be subtle. Systemic effects
may result from several biological mechanisms of action. For
example, it is hypothesized that extra-pulmonary effects may be
local responses to systemic circulation of cytokines and acute
phase proteins that are synthesized in the lungs. The systemic
effects may also be the result of direct interaction of translocated
NPs with the surrounding biological milieu (Jackson et al., 2013).
However, no previous study has simultaneously investigated both
translocation of NPs and systemic effects in heart and liver
tissues. Thus, the second objective of this study was to employ
genomics tools to profile the entire transcriptomic response in
heart and liver tissues of these mice to identify and characterize
the mechanisms of systemic effects. Global gene expression
profiling has the added advantage of potentially identifying
toxicities or potential health risks that might not be found using
the traditional end-point-specific techniques.
C57BL/6 mice were exposed via intratracheal instillation to 18
or 162mg of nano-TiO2. Lungs, hearts and livers were sampled
24 h and 28 d after the exposure. Particle retention in lungs and
pulmonary responses were published previously (Husain et al.,
2013; Saber et al., 2012). In this study, we used nano-scale
hyperspectral microscopy to detect translocation of nano-TiO2 to
heart and liver tissues, and profiled global mRNA response to
reveal possible adverse effects in these tissues.
Materials and methods
Characterization of materials
The details of sample preparation and particle characterization
were described previously (Halappanavar et al., 2011; Hougaard
et al., 2010). In brief, the nano-TiO2 used in this study is also
known as UV-Titan L181 (Kemira, Pori, Finland). Transmission
electron microscopy (TEM, Tecnai G20, FEI Company,
Hillsboro, OR) was used to determine particle size, morphology,
and agglomeration and/or aggregation state in suspension. Powder
X-ray diffraction (XRD) was used to determine crystalline phase
and size. Multipoint Brunauer, Emmett and Teller (BET) nitrogen
adsorption method (after 1 h degassing at 300 C) was employed
to determine specific surface area on a Quantachrome Autosorp-1
(Quantachrome GmbH & Co. KG, Odelzhausen, Germany).
Elemental composition was analyzed using X-ray fluorescence
(Philips PW-2400 spectrometer); this service was provided by the
Department of Earth Sciences, University of Aarhus, Denmark.
Animal handling, exposures and tissue collection
Details of animal handling, exposures and tissue collection have
been described previously (Husain et al., 2013; Jackson et al.,
2011; Saber et al., 2012). Briefly, particles were suspended by
probe sonication in 0.9% NaCl MilliQ water containing 10% v/v
acellular BAL collected from C57BL/6 mice and 8-week-old
female C57BL/6 mice (Taconic Ry, Denmark) were exposed to two
different doses (18 and 162mg) of nano-TiO2 via intratracheal
instillation (N¼ 6 per group). Control mice were exposed to
vehicle solutions containing 90% of 0.9% NaCl MilliQ water and
10% acellular BAL fluid. Female mice were chosen as they can be
co-housed and are easier to handle. We have used both male and
female mice previously and we have not observed any obvious
differences in pulmonary response. The doses used in this study are
equivalent to 1.5 and 15 working days at the Danish occupational
exposure level for nano-TiO2 (6.0 mg Ti/m
3–10 mg TiO2/m
3),
respectively (At vejledning, 2007). Mice were sacrificed under
anaesthesia using Hypnorm (fentanyl citrate 0.315 mg/ml
and fluanisone 10 mg/ml from Janssen Pharma) and Dormicum
(Midazolam 5 mg/ml from Roche) 24 h and 28 d post-exposure
as described previously (Husain et al., 2013; Jackson et al., 2011;
Saber et al., 2012). Liver and heart tissues from experimental
and control mice were placed in cryogenic vials and snap frozen
immediately in liquid nitrogen. All tissues were stored at 80 C
until the analysis. All animal experiments were approved by
the Danish ‘‘Animal Experiments Inspectorate’’ and performed
according to their guidelines for ethical conduct in the care and
use of animals in research (application # 2010/561-1779).
Particle size distributions in the exposure medium were
analysed using dynamic light scattering (DLS, Malvern zetasizer
Nano ZS equipped with a 633 nm He-Ne laser, Malvern Inc., UK)
as detailed in (Roursgaard et al., 2010). The results were
calculated using Malvern DTS software version 6.11 and 7.11.
The intensity-derived average hydrodynamic diameters, Zave (zeta
potential), and polydispersivity indices (PDI) of each of the
dispersions used for toxicological testing were derived.
Preparation of blood smears and serum
In a separate animal exposure experiment (approved by Animal
Experiments Inspectorate), 5–7 weeks old female C57BL/6 mice
were exposed by intratracheal instillation to 162mg of nano-TiO2
(N¼ 3) or control exposure medium (N¼ 3) as described above.
Blood was drawn from control and treated mice by cardiac
puncture under anaesthesia using a 1 ml syringe 4 h and 24 h after
the instillation. A drop (5 ml) of blood was placed on a frosted
microscope slide and was spread on the surface using another
slide. Smears were air dried, and then dipped into 100% methanol
for 1 min. Slides were left to dry overnight and stored at room
temperature until use. A minimum of one slide per mouse was
prepared and assessed. The rest of the blood was collected in a
microtainer tube with serum separator (Becton Dickinson and
Company, NJ). Blood was allowed to clot for 30 min at room
temperature and centrifuged at 3000 g for 15 min at 4 C to
collect the serum.
Detection of nano-TiO2 particles in the tissues
The translocation of nano-TiO2 to liver, heart tissue and blood
were assessed using CytoViva’s Nano-scale Hyperspectral
Microscope (CytoViva, Inc., Auburn, AL). Frozen liver and
heart tissues from control and nano-TiO2 exposed C57BL/6 mice
were randomly cryo-sectioned into 5 mm thick slices, fixed with
formalin and stained with hematoxylin–eosin (H-E) stain. In order
to avoid bias in the analysis, coded H-E stained slides (two
sections per sample) were sent to CytoViva, Inc. for hyperspectral
imaging and qualitative mapping of nano-TiO2 particles. Blood
smears prepared as described above were analysed by CytoViva,
Inc. Prior to the analyses, a reference spectral library of nano-TiO2
used in the study, as well as nano-TiO2 found in both tissue types,
and blood samples, was created based on the different refractive
index of nano-TiO2 in experimental samples as previously
described (Husain et al., 2013). From each treatment group, one
non-coded experimental sample was used for this purpose.
A second hyperspectral library was created from several regions
of tissue sections or blood smears prepared from control mice (not
exposed to nano-TiO2), which included spectral profiles of bright
non-specific objects in the background (cells, stains and debris).
Hyperspectral profiles of coded experimental samples were
compared to those in the two reference libraries. Samples were
decoded after the completion of the analysis to examine particle
retention.
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RNA extraction, microarray hybridization and data
analysis
Total RNA was isolated from randomly sectioned (weighing
10–15 mg) liver and heart tissues from control and nano-TiO2
exposed C57BL/6 mice using TRIzol reagent (Invitrogen,
Carlsbad, CA), and purified using RNeasy Plus Mini kits
(Qiagen, Mississauga, ON, Canada) according to the manufac-
turer’s instructions. Total RNA concentration was measured using
a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific
Inc., Wilmington, DE), and RNA quality was assessed using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa
Clara, CA) according to the manufacturer’s instructions. Samples
showing RNA integrity numbers (RIN) of 7 and above were used
in microarray and RT-qPCR experiments. DNA microarray
(Agilent mouse 4 44 K oligonucleotide microarrays; Agilent
Technologies Inc., Santa Clara, CA) analysis was conducted as
described previously (Husain et al., 2013). All microarray data
from this study are available at the National Center for
Biotechnology Information (NCBI) and Gene Expression
Omnibus (GEO) databases. GEO accession numbers for these
files are: GSE56324 (for heart dataset) and GSE56325 (for liver
dataset). A sample size of five animals per group was used for the
microarray experiments. Based on our previous studies, we have
found that a minimum of n¼ 5/treatment group is optimal and
provides sufficient statistical power to detect subtle gene expres-
sion changes. A sample size of five is also operationally feasible.
The microarray results were validated as described in the sections
below by RT-PCR, ELISA and Bioplex analysis using n¼ 3–5/
treatment group, which is standard.
A randomized reference block design was used to analyze
gene expression microarray data. Data were normalized using
LOWESS regression modeling method and statistical signifi-
cance of the differentially expressed genes was determined
using MAANOVA in R statistical software (http://www.r-
project.org). The Fs statistic was used to test the treatment
effects and p values were estimated by the permutation method
using residual shuffling. Fold change calculations were based on
the least-square means. Genes showing expression changes of at
least 1.5-fold in either direction compared to their matched
controls and having p values ( 0.05) were considered signifi-
cantly differentially expressed and were used in the downstream
analysis.
Gene ontology (GO) analysis using the Database for
Annotation, Visualization and Integrated Discovery (DAVID)
v6.7 (Huang et al., 2009) was performed to identify functional
themes to which the differentially expressed genes belonged.
Specific biological pathways associated with the differentially
expressed genes were identified using Ingenuity Pathway Analysis
(IPA, Ingenuity Systems, Redwood City, CA) software. Biological
network analysis was conducted using MetaCore software
(Thomson Reuters Scientific Inc., Philadelphia, PA).
Validation of genes by RT-qPCR
A custom quantitative real-time RT-PCR (RT-qPCR) array
(CAPM11804; Qiagen, Frederick, MD) was designed to validate
26 genes representing complement cascade, pro-inflammatory
chemokines, cytokines and their receptor groups from the
microarray data sets (± 1.5 fold; p50.05). The experiment was
carried out according to the manufacturer’s instructions as
described previously (Husain et al., 2013). Normalization of the
threshold cycle (Ct) values was performed using Hprt, Actb and
Gapdh as internal control genes. Relative expression of the
differentially expressed genes was determined using PCR array
data analysis template available online from the manufacturer’s
website (Qiagen, Frederick, MD).
Western blot analysis of complement factors and
inflammatory modulators in heart tissue and serum
Total protein was extracted from the frozen mouse heart tissue
sections of experimental and control mice using Bio-Plex Cell
Lysis Kits (BioRad Laboratories, Mississauga, ON, Canada)
containing a protease inhibitor cocktail (1:200; Sigma Aldrich,
Oakville, ON, Canada). Bradford protein assay kits (BioRad
Laboratories, Mississauga, ON, Canada) were used for quantifi-
cation of the extracted protein. Approximately, 30–50 mg of total
protein was run on 4–15% SDS-PAGE (BioRad Laboratories,
Mississauga, ON, Canada) and was transferred onto Immuno-Blot
PVDF membrane (BioRad Laboratories, Mississauga, ON,
Canada) by wet transfer. Antibodies for anti-C2, anti-MASP1
and anti-MASP-2 from Santa Cruz Biotechnology, Inc. (Dallas,
TX), anti-C4b from Sigma (St. Louis, MO), anti-C3 and anti-C5
from Abcam (Toronto, ON, Canada), were used to test for changes
in expression levels of these proteins. All expression values were
normalized to total GAPDH levels (anti-GAPDH antibody, R & D
Systems Inc., MNUSA) in Image Lab software version 4.1 build
16 (BioRad Laboratories, Mississauga, ON, Canada).
Enzyme linked immune sorbent assay
Enzyme linked immune sorbent assay (ELISA) was used to
measure the total levels of adiponectin, adipisin (complement
factor D) and leptin from EMD Millipore Corporation (Billerica,
MA), fibrinogen (Abcam Inc., Toronto, ON, Canada) and resistin
(R&D Systems Inc., Minneapolis, MN), in heart of the experi-
mental and control mice. ELISA was performed according to the
individual manufacturer’s instructions.
Expression analysis of inflammatory proteins using
multiplex protein array
Total protein was isolated from both control and treated samples
as described above. A multiplex suspension protein assay was
performed using the 23-plex panel of Bio-Plex Pro Mouse
Cytokine Assays (Bio-Rad, Mississauga, ON, Canada) according
to the manufacturer’s instructions. The details of the experiment
are described in Husain et al. (2013).
Results
Particle characterization
Detailed characterization of the nano-TiO2 was reported by
Hougaard et al. (2010) and Halappanavar et al. (2011). Briefly,
the nano-TiO2 used for this study was surface modified with
zirconium, silicon, aluminum and polyalcohol, and mainly
consisted of the rutile form (70.8% by weight). It had a primary
size of 20.6 nm and surface area of 107.7 m2/g. Details are
summarized in Table 1.
Table 2 summarizes the DLS results of the average intensity-
derived hydrodynamic sizes of the nano-TiO2 dispersed in
exposure medium. The results show high degree of agglomeration
at all concentrations tested. Formation of aggregates and
agglomerates of nano-TiO2 was confirmed by TEM.
Detection of nano-TiO2 in heart and liver tissues
Nano-scale hyperspectral microscopy enables accurate detection
of pristine NPs in biological samples without a need for
fluorescence tagging. Using this system, we examined liver and
heart tissues from mice exposed intratracheally to 18 and 162 mg
of nano-TiO2 sampled on day 1 and 28 post-exposure, respect-
ively, for evidence of translocation as well as mice exposed to
vehicle. Figure 1 shows optical and hyperspectral images of liver
(Figure 1a) and heart (Figure 1b) tissues from mice exposed to
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nano-TiO2. The top panel is the spectral library of light scattering
in the control untreated tissues (Figure 1a and b left), and the
spectral library of nano-TiO2 used in the study in exposed liver
(Figure 1a, right) and heart (Figure 1b, right) tissues. The middle
panel shows darkfield hyperspectral images. The bottom panel
shows hyperspectral mapping images (overlay of darkfield
hyperspectral images with nano-TiO2 reference spectra). The red
colour in the bottom panel (white arrows) indicates areas of
spectra that matched to the specific hyperspectral reference
library created for nano-TiO2 in these tissues. The hyperspectral
imaging of tissues revealed the presence of notable amounts of
nano-TiO2 in the livers of mice exposed to the 18 and 162mg
doses sampled 24 h post-exposure; detectable amounts of nano-
TiO2 were sustained in the liver for up to 28 d after the exposure
(Figure 1a). Likewise, translocation of nano-TiO2 to heart was
confirmed at both doses and post-exposure time points; however,
in comparison to liver, only trace amounts of nano-TiO2 were
detected in the heart tissue (Figure 1b). The distribution of
particles within the tissues was non-uniform. Relatively larger
fraction of nano-TiO2 was detected following exposure to 162mg
compared to 18mg dose. Although notable differences were
observed at the two post-exposure time points, the exact
quantification of the amount of translocated nano-TiO2 was not
possible. Thus, it is not clear if the amount of translocated NPs
decreased or increased with time. As expected, no nano-TiO2 was
detected in control mice. Thus, nano-TiO2 was translocated from
lungs to heart and liver following intratracheal instillation.
Biological impacts of translocation
In order to elucidate the biological consequences of nano-TiO2
translocation, we used DNA microarrays to profile cardiovascular
and hepatic global genomic responses in mice exposed to 162 mg
of nano-TiO2 sampled 24 h, and 28 d post-exposure. Since the low
dose was expected to induce such subtle effects, only the high
dose samples were analysed. A total of 458 genes in heart (264
genes at 24 h and 275 genes at 28 d) and 63 genes in liver
(49 genes at 24 h and 14 genes at 28 d) were statistically
significantly differentially expressed (p 0.05 and fold change of
1.5 in either direction). The details of the microarray results are
provided in Supplementary material (Supplementary Figure S1
and Tables S1–3). Ingenuity Pathway Analysis software
(Ingenuity Systems, Redwood City, CA) was used to categorise
and assign differentially expressed genes to specific pathways.
Four main canonical pathways were significantly altered (Fisher’s
exact p value  0.05) in heart including complement cascade,
acute phase signalling, hepatic fibrosis and TR/RXR activation
(Figure 2a). Liver tissue showed changes in the expression of
several genes associated with acute-phase response (Saa1, Saa2
and Saa3); however, no specific pathways were significantly
enriched in the liver. Since the liver showed a very subtle
response, the rest of the analysis was conducted on heart tissues.
In the heart tissue, the complement cascade was the most
perturbed pathway, with a total of seven differentially expressed
genes, including complement factor D or adipsin (Cfd), comple-
ment factor 3 (C3), Cfb, C4b, C1qa, Cfh and C2 (Figure 2b).
Up-regulation of these seven genes was evaluated using RT-
qPCR. In addition, 19 more genes belonging to the complement
pathway and inflammation were selected for validation by RT-
qPCR. Inflammatory genes were included in the validation since
it is known that the complement-driven immune response includes
activation of inflammation. However, these genes did not show
statistically significant differential expression by RT-qPCR
(Supplementary Table S4). The results confirmed significant
(p 0.05) up-regulation of C1qa, C2, C3, C4b, Cfb and Cfh in
heart tissue at 24 h post-exposure (Figure 2b). Although we
observed a very high expression of Cfd (1880-fold; p¼ 0.12) and
Adipoq (38-fold; p¼ 0.07) by RT-qPCR, statistical significance of
these genes did not meet the p value threshold of 0.05; failure to
attain statistical significance was due to inter-animal variation and
the small number of animals used in this experiment. In addition,
C1ra, C1qb, Serpineg1 and Cxcl1 were identified as differentially
expressed 24 h post-exposure only by RT-qPCR (Supplementary
Table S4). To evaluate the impact at the protein level, the
corresponding protein levels of the above genes were assessed
using ELISA or Western blot analysis. In addition, we assessed
protein levels of several other complement genes that exhibited
greater than 2-fold changes in gene expression compared to their
respective controls (Figure 3a). Protein analysis by Western blot
Table 1. Detailed physical and chemical characteristics of nano-TiO2
(UV-Titan L181) particles (modified from Halappanavar et al., 2011;
Hougaard et al., 2010; Husain et al., 2013).
Properties Description/composition
Phase Rutile
Product form Powder
Color White
Odour Odourless
Structural formula Ti2O4
Average crystalline size 20.6 ± 0.3 nm
Minimum crystalline size [100]a 14.4–15.5 nm
Maximum crystalline size [001]a 38.4 nm
Specific surface area 107.7 m2/g
Surface coating Si, Al, Zr and Polyalcohol
Classification Pigment White 6
Elemental composition Concentrations [wt%]
Titanium (Ti) 42.44
Oxygen (O2)
b 35.24
Silicon (Si) 5.61
Aluminum (Al) 2.42
Zirconium (Zr) 0.86
Sodium (Na) 0.45
LOI 5.19
LOI, loss on ignition.
aEstimate of the average crystalline size along the shortest and longest
crystallographic direction.
bCalculated by difference from 100 wt%.
Table 2. Dynamic light scattering analysis of particle size distributions in the exposure medium.
Zave (PDI)
nano-TiO2 18mg 54 mg 162 mg
Not filtered 3128 ± 273 (0.451) 1630 ± 192 (0.223) 4147 ± 1260 (0.882)
Filtered with 3.1mm 1023 ± 28 (0.250) 1024 ± 201 (0.680) 1362 ± 221 (0.253)
Filtered with 0.2mm 181 ± 3 (0.135) 50.4 ± 19 (0.997) 1551 ± 406 (0.722)
The results include PDI values before and after filtering using 3.1mm or 0.2 mm filters.
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confirmed the altered levels of C2A, C3, C3B, C4B, C5,
C5B, mannan-binding lectin serine peptidase 1 (MASP-1) and
MASP-2, in heart tissues of nano-TiO2 exposed mice 24 h post-
exposure (Figure 3a). Significant (p 0.05) up-regulation of CFD
(Adipsin) was confirmed by ELISA (Figure 3b). Since early
complement activation plays an important role in promoting
inflammation, expression levels of several inflammatory
modulators (cytokines and chemokines) were validated using
multiplex protein arrays. A total of 23 proteins associated with
inflammation were assessed in heart tissues at the 24 h post-
exposure time point. A list of all proteins evaluated by multiplex
protein array (Bioplex) and ELISA is provided in Supplementary
Table S5. The results confirmed significantly (p 0.05)
up-regulated expression of CXCL1, CCL2, CCL3, CCL4,
Figure 1. Detection of nano-TiO2 particles in heart and liver tissues using Nano-scale Hyperspectral Microscopy. Liver and heart tissues from mice
exposed to 18 and 162 mg of nano-TiO2 via intratracheal instillation and sampled 1 d (24 h) and 28 d post-exposure. Microscopic slides containing
approximately 5mm tissue sections were subjected to visible and near-infrared hyperspectral imaging to detect the particles in (a) liver and (b) heart
tissues. Top panels in both (a) and (b) show spectral libraries from control (left image) and nano-TiO2 exposed (right image) tissues, respectively.
Middle panels for the same show dark field hyperspectral images from control and nano-TiO2 exposed tissues. Bottom panels show hyperspectral
mapping of nano-TiO2 in the (a) liver and (b) heart tissues; nano-TiO2 appear as red dots or aggregates indicated with white arrow heads.
DOI: 10.3109/17435390.2014.996192 Translocation of nano-TiO2 and induction of systemic immune responses 1017
IL-1b, IL-5, IL-10, IL-12 (p40), IL-13 and TNF-a at the 24 h
post-exposure time point (Figure 3b). Most of these are regulated
by the NFkB pathway. All of the changes in genes and proteins
observed 24 h post-exposure were returned to basal level by 28 d
post-exposure (data not shown), suggesting that activation of
complement cascade and consequent inflammation mediated by
NFkB may reflect an acute response that rapidly declines even in
the absence of complete particle clearance. A similar decline in
inflammation was also observed in lungs in the presence of
particles (Husain et al., 2013).
Particle translocation from lungs to other tissues is suggested
to occur via blood circulation (Sadauskas et al., 2009b). To test
this hypothesis, we exposed mice via intratracheal instillation to
162mg of nano-TiO2 and collected blood 24 h post-exposure. We
assessed the presence of particles in blood smears using the Nano-
scale Hyperspectral Microscope. Figure 4 shows trace amounts of
Figure 3. Analysis of proteins by Western
blot, ELISA and multiplex protein array. (a)
Proteins involved in complement cascade in
the heart tissue at 24 h post-exposure were
analyzed by Western blot. (b) Pro-inflam-
matory chemokines and cytokines (CXCL1,
CCL2, CCL3, CCL4, IL-1 b, IL-5, IL-10,
IL-12 [p40], IL-13 and TNF-a) were ana-
lyzed using 23-plex bioplex assay kit;
expression of adipsin (CFD) was analyzed
using ELISA. The statistical significance is
noted by **p50.01 or *p50.05.
Figure 2. Pathway analysis and RT-qPCR validation of complement cascade genes. (a) Ingenuity pathway analysis shows significant enrichment of
complement cascade pathway in the heart tissue 24 h post-exposure. (b) Validation of genes in the complement cascade pathway by RT-qPCR. The
statistical significance is noted by **p50.01 or *p50.05.
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particles in blood at the 24 h post-exposure. The very low levels of
particles detected can be attributed to the fact that particles
entering into blood circulation accumulate in the liver relatively
quickly and thus, may only stay in circulation for a very brief
period of time (Sadauskas et al., 2007). Complement factors are
secreted into blood from the liver and/or adipose tissue. These
factors can be activated in blood by binding to pathogens or
particles. In order to assess if the presence of particles in blood
activated the complement cascade, we measured levels of
activated C3 in serum samples collected 24 h post-exposure.
Western blot analysis using C3-specific antibodies showed
significant reduction (p 0.05) of the native/pre C3 protein into
its cleavage product C3B, which is a hallmark of complement
activation (Figure 3a), suggesting that the nano-TiO2 activated
serum complement cascade.
Discussion
Several studies have shown that NPs entering the body via
pulmonary exposure reach extra pulmonary tissues including
blood, liver, kidney, brain, diaphragm and heart (Kreyling et al.,
2002; Mercer et al., 2013; Oberdorster et al., 2002; Semmler
et al., 2004; Semmler-Behnke et al., 2007; Takenaka et al., 2006).
Most of these studies used NPs tagged with fluorescence labels or
isotope, and it has been shown that leaking or dissociation of the
label from NPs can occur and skew the interpretations of such
data (Levy et al., 2012). In addition, the limit of detection of NPs
using the existing analytical or microscopic methods is 1% of
the total administered dose (Nemmar et al., 2002a). For example,
we previously evaluated the translocation of nano-TiO2 to the
liver using ICP-MS and found no evidence of translocation
(Hougaard et al., 2010). This may have been due to a high
detection limit caused by interference from other molecules with
similar molecular weight. However, in this study, we instilled
mice with the same nano-TiO2 particles, and used Nanoscale
Hyperspectral Microscopy to detect a considerable amount of
particle translocation to both liver and heart tissues. The results
suggest that the technology may be more sensitive in detecting
traces of particles for which there is a high background level in
biological tissues, or which cannot be easily detected using ICP-
MS, such as carbon nanotubes and nano-TiO2.
Figure 4. Detection of nano-TiO2 in blood of
mice exposed to high dose (162mg) nano-
TiO2. Fresh drops of blood from nano-TiO2
exposed or control mice were smeared on
microscopic slides using cover slips. Slides
were subjected to visible and near-infrared
hyperspectral imaging to detect the presence
of particles at 24 h post-exposure. The top
panel shows the spectral libraries from con-
trol (left) and nano-TiO2 exposed (right)
samples. The middle panel shows dark field
images from control and exposed samples.
The bottom panel (right) sample shows
hyperspectral mapping of nano-TiO2 in the
blood of exposed mice; nano-TiO2 appear as
red dots or aggregates.
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Pulmonary exposure to NPs has been shown to induce adverse
systemic effects in non-target tissues, such as heart, liver and
brain. Inhalation or intratracheal instillation of nano-TiO2 (21 nm)
or carbon black (Printex 90) results in oxidative stress, and
genotoxicity in various tissues including coronary arterioles, liver
and skeletal muscle (Bourdon et al., 2012; Cao et al., 2014;
Jackson et al., 2012b; LeBlanc et al., 2009, 2010; Mikkelsen et al.,
2011; Moller et al., 2010; Nurkiewicz et al., 2006; Vesterdal et al.,
2010). In utero exposure to nano-TiO2 or carbon black has been
shown to affect global gene expression profiles in the livers of
newborn offspring (Jackson et al., 2012a, 2013). It is unclear
whether the observed systemic effects are caused by direct
interaction of these distal tissues with translocated NPs or are the
results of local pulmonary inflammation and acute phase response
leading to infiltration of circulating inflammatory cells and
activation of signalling cascades. Direct particle translocation is
proposed to play a role in inducing these systemic effects;
however, none of the above studies have confirmed the presence
of particles in the tissues where an effect was observed. In the
absence of confirmed particle translocation, adverse systemic
effects are assumed to be the result of the downstream
consequences of local pulmonary inflammation. In the present
experiment, nano-TiO2 particles were detected both in liver and
heart. Despite the fact that a large amount of nano-TiO2 was
observed in the liver compared to heart tissue, the resulting effects
on hepatic gene expression changes were relatively subtle. The
hepatic system is the detoxification center of the body. Thus, the
liver may be well equipped to deal with NPs translocated from the
lungs. The considerable amount of nano-TiO2 found in liver up to
28 d after the last exposure suggests a slow clearance similar to
what has been documented for gold NPs (Sadauskas et al., 2009a).
Another study showed that the largest distribution of NPs in
experimental rats following intravenous injection of nano-TiO2
was to the liver; with levels remaining unchanged 1, 14 and 28 d
post-injection (Fabian et al., 2008).
In contrast to the liver, the heart exhibited expression changes
in several genes and proteins associated with the complement
cascade following nano-TiO2 in our study. The complement
system consists of a large number of plasma proteins (35) that
activate one another to opsonise foreign objects (pathogens and
nanoparticles presumably recognized as pathogens) or damaged
host cells, and induce inflammatory responses that help to fight
infection (Janeway & Medzhitov, 2002). The complement system
can be activated on the pathogen/NP surface by three distinct
pathways: classical, lectin or the alternative pathway (Figure 5).
These pathways are activated by different initiators, but eventually
converge to generate the same effector molecules. Early events of
the complement activation by any of these pathways lead to the
generation of C3 convertase, which in turn leads to C3B, the
pivotal effector molecule and C3A, an inflammation mediating
peptide (Noris & Remuzzi, 2013). C3B also binds to C3
convertase and forms C5 convertases, C5A and C5B, all of
which play an important role in inflammation and late events of
the complement system (Noris & Remuzzi, 2013). Activated
Figure 5. A biological network showing interactions among complement cascade and inflammatory cascade genes/proteins. Red circle: up-regulation,
green circle: down-regulation, both red and green: down-regulation of precursor and induction of the activated form. These genes were differentially
regulated in this study. No circle: no change in expression or expression levels not measured in this study. Green arrows represent positive regulation/
activation, brown arrows represent negative regulation/inhibition and grey arrows represent unspecified regulation. B – binding; C – cleavage; IE –
influence on expression; CS – complex subunit; CR – complex group relations.
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complement system protects against pathogenic substances by
directly binding and opsonising the pathogen for phagocytic
engulfment, or by recruiting and activating phagocytes to the site
of complement activation. Figure 5 illustrates molecules asso-
ciated with three distinct complement pathways in general and
highlights that specific genes/proteins that exhibited altered
expression levels following exposure to nano-TiO2 in this study
are associated with the lectin pathway. These results suggest that
the lectin pathway may be the preferred pathway for opsonisation
and clearance of NPs from the cardiovascular system.
Increased protein levels of C3 have been found previously in
lung tissue after repeated pulmonary exposure to single walled
carbon nanotubes by aspiration (Teeguarden et al., 2011). The
authors of this study also noted increased expression of several
other acute phase proteins including FN1, S100A8 and S100A9.
Complement activation and consequent inflammation are a part of
the acute phase response, which aids in the clearance of invading
pathogens from tissues and circulation. However, uncontrolled
complement activation and resulting inflammation have been
shown to cause adverse cardiovascular effects such as, the
development and progression of atherosclerosis, plaque rupture
and thrombosis (Carter, 2012). For example, C3 activation
products (C3a and C3b) are involved in the atherothrombotic
process and their association with lipid components in the vessel
wall can expedite the atherosclerotic process (Carter, 2012). The
results of our study reflect an acute scenario; however, the long-
term effects of persistent activation of the complement cascade
following chronic exposures to NPs are yet to be demonstrated.
The results further imply that translocation of particles may
have played a direct role in the observed systemic effects in both
liver and heart. However, additional experiments that can
effectively by-pass the pulmonary system, or experiments
involving transgenic mice that are deficient in their ability to
induce acute phase and/or immune response, are required to
conclusively rule out the potential involvement of lung neuronal
signalling that is known to induce systemic immune response.
Indeed, we have reported a strong acute phase reaction in the
lungs of these mice (Husain et al., 2013) that may have triggered
the lung neuronal axis and consequently the systemic response.
In addition to exposure to NPs in consumer products and via
inhalation, NPs can be directly injected intravenously during
nano-medicine applications (Zolnik et al., 2010). Following entry
into the blood by direct injection or indirect translocation, NPs
can bind to plasma proteins (opsonisation by complement
proteins, immunoglobulins, apolipoproteins and mannose binding
proteins) and immune cells (monocytes, platelets and leukocytes)
that are responsible for their uptake and elimination from the
circulation (Zolnik et al., 2010). Thus, with increasing use of NPs
for medicinal and diagnostic purposes, there is an increasing risk
of persistently activating the complement system, which may
further impose a negative chronic health outcome. Given the
results of this study showing the ability of trace amounts of NPs to
induce the complement system in blood and heart tissue, a
detailed understanding of the interactions between the NPs and
the complement system will be important.
Conclusion
In conclusion, we demonstrate that a small fraction of nano-TiO2
particles translocate from lungs to blood and extra-pulmonary
organs, which is in line with reports published earlier (Muhlfeld
et al., 2007; Nemmar et al., 2002a; Rothen-Rutishauser et al.,
2007; Sadauskas et al., 2009b; Semmler-Behnke et al., 2008). We
further show that acute translocation of particles to blood and
other organs coincides with induction of an innate immune type
response, which includes activation of acute stress response in
liver, C3 activation in blood and the activation of complement
cascade and inflammation response in the heart tissue, all of
which are involved in particle recognition and clearance.
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